Can triple therapy help patients with unresectable hepatocellular carcinoma live longer?
Triple therapy combines transarterial chemoembolization (TACE) with targeted drugs (like lenvatinib, donafenib, or sorafenib) and immunotherapy (PD-1 inhibitors). For patients with unresectable hepatocellular carcinoma (uHCC), this combination has shown promise in extending survival. Multiple studies report that triple therapy improves overall survival and progression-free survival compared to TACE alone or TACE plus a targeted drug alone 237. However, the benefit may depend on the patient's cancer stage and other factors.
What the research says
A large multicenter study found that triple therapy (TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors) significantly improved overall survival (hazard ratio 0.43) and progression-free survival (15.9 vs. 8.0 months) compared to TACE alone in patients with intermediate or advanced stage HCC 7. Another study comparing TACE plus donafenib and camrelizumab (a triple therapy) versus TACE plus donafenib alone showed that the triple therapy group had a longer median overall survival (23.1 vs. 12.0 months) and longer progression-free survival (13.0 vs. 7.8 months) 3. A phase II trial reported that TACE combined with camrelizumab and rivoceranib doubled progression-free survival compared to TACE alone (10.8 vs. 3.2 months) 4. A meta-analysis of Chinese patients who underwent surgery after triple therapy found high 1-year (92%) and 2-year (84%) overall survival rates, though median survival was not reached in most studies 6. However, one study noted that triple therapy did not show a survival benefit over TACE alone in patients with early-stage HCC 7. Additionally, patients with hepatitis B virus (HBV) infection may have higher surgical conversion rates after triple therapy 1.
What to ask your doctor
- Is triple therapy (TACE plus targeted therapy and immunotherapy) a suitable option for my stage of liver cancer?
- What are the potential side effects of this combination treatment, and how are they managed?
- How does my hepatitis B status affect the likelihood of benefit from triple therapy?
- What are the chances that triple therapy could make my tumor resectable, allowing for surgery?
- Are there any clinical trials or newer drug combinations that might be more effective for my specific situation?
This question is drawn from common patient questions about Gastroenterology and answered using cited medical research. We do not provide individualized advice.